Enfermedades Autoinmunes, Inflamatorias e Infecciosas » Artropatías Inflamatorias y Artritis Inducidas por Microcristales
Coordinador de Grupo
Fernando Pérez Ruiz
Doctor en Medicina
OSI Eskerraldea Enkarterri Cruces
Contacto
(0034) 94 600 6000
Miembros del Grupo
Alberto Alonso Ruiz
Joana Atxotegi Saenz de Buruaga
Boris Anthony Blanco Cáceres
Marcelo Calabozo Raluy
Sandra Pamela Chinchilla Gallo
Ana María Herrero Beites
Elena Garmendia Sanchez
Rosario López Santamaría
Líneas de Investigación
Artropatías microcristalinas – gota y artritis por pirofosfato.
Clasificación clínica de la gota dependiendo del manejo renal de urato.
Eficacia de los fármacos hipouricemiantes.
Determinación de los niveles adecuados para el control de la uricemia durante el tratamiento.
Establecimiento de distintas dianas terapéuticas de uricemia para tratamiento y prevención a largo plazo de la uricemia.
Factores de riesgo de mortalidad.
Desarrollo y validación de medidas de desenlace para el tratamiento hipouricemiante.
Medición de los tofos subcutáneos mediante calibradores y de los depósitos articulares mediante ecografía y resonancia nuclear magnética.
Actividades del Grupo
Publicaciones Científicas

Perez-Ruiz F, Kandaswamy P, Gurunath RK, Burton H, Jansen T. A summary of clinical evidence for commonly used uricosurics for gout in europe. Ann. Rheum. Dis. 2018; 77(2): 1045 - 1045 MEETING ABSTRACT.

Perez-Ruiz I, Meijide S, Hernandez ML, Navarro R, Ferrando M, Larreategui Z, et al. Antioxidant status of human follicular fluid: natural versus controlled ovarian hyper-stimulated cycles. Free Radic. Biol. Med. 2018; 120(1): 62 - 62. MEETING ABSTRACT.

Perez-Ruiz F, Chinchilla SP, Atxotegi J. Association between hfe genotypes and clinical severity characteristics of calcium pyrophosphate crystal arthritis. Ann. Rheum. Dis. 2018; 77(2): 140 - 141. MEETING ABSTRACT.

Perez-Ruiz F, Atxotegi J. Association of HFE Genotypes with Clinical Severity in Patients with Definite Calcium Pyrophosphate Arthritis. Arthritis Rheumatol.. 2018; 70(9). MEETING ABSTRACT.

Perez-Ruiz F, Richette P, Karra RG, Wild I, Hagedorn H, Kandaswamy P, et al. Effect of serum uric acid (sua) on gout flares (gf) and tophi resolution in gout patients. Pooled post hoc analysis of clear 1 & clear 2 trials. Ann. Rheum. Dis. 2018; 77(2): 658 - 659. MEETING ABSTRACT.

Sanmarti R, Tornero-Molina J, Narvaez FJ, Munoz A, Garmendia E, Ortiz-Garcia AM, et al. Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations. Arthritis Rheumatol.. 2018; 70(9). MEETING ABSTRACT.

Kiltz U, Perez-Ruiz F, Uhlig T, Jansen TL, Karra R, Schmedt N, et al. Epidemiology, treatment, and health resource use of gout patients in germany: results from analysis of a claims database. Value Health. 2018; 21: 7 - 7. MEETING ABSTRACT.

Shaukat A, Gosling A, Bixley M, Phipps-Green A, Major TJ, Cadzow M, et al. Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Perez-Ruiz F, Richette P, Stack A, Gurunath RK, Yprous MJGD, Carmona L. Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Perez-Ruiz I, Martinez G, Hernandez ML, Navarro R, Ferrando M, Larreategui Z, et al. Human granulosa cells express proteins of the paraoxonase family. Free Radic. Biol. Med. 2018; 120(1): 138 - 138. MEETING ABSTRACT.

Perez-Ruiz F, Sanchez-Piedra CA, Sanchez-Costa JT, Andrés M, Diaz-Torne C, Jimenez-Palop M, et al. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. Rheumatol. Ther.. 2018; 5(1): 243 - 253. FI: (Q). DOI: 10.1007/s40744-017-0091-1.

Perez-Ruiz F, Desideri G. Improving adherence to gout therapy: an expert review. Therap. Clin. Risk Manag.. 2018; 14: 793 - 802. FI: 1,995(Q3). DOI: 10.2147/TCRM.S162956. REVIEW.

Chinchilla SP, Atxotegi J, Onaindia IU, Perez-Ruiz F. Rheumatology talks to the community: results of an educational intervention. Ann. Rheum. Dis. 2018; 77(2): 868 - 868. MEETING ABSTRACT.

Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann. Rheum. Dis. 2018; 77(6): 914 - 921. FI: 12,350(Q1). DOI: 10.1136/annrheumdis-2017-212245.

Zaidi F, Phipps-Green A, Tausche AK, So A, Riches P, Andres M, et al. Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Kumar AUA, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018; 13(5): e0198197. FI: 2,766(Q1). DOI: 10.1371/journal.pone.0198197.

Kiltz U, Perez-Ruiz F, Uhlig T, Jansen TL, Gurunath RK, Schmedt N, et al. The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany. Arthritis Rheumatol.. 2018; 70(9). MEETING ABSTRACT.

Uson J, Garmendia E, Moragues C, de Agustin JJ, Mayordomo L, de Miguel E, et al. To what extent is interobserver reliability for detecting ultrasound urate crystal deposits dependent on the experience of the ultrasonographer?. Ann. Rheum. Dis. 2018; 77(2): 809 - 809. MEETING ABSTRACT.

Perez-Ruiz F, Moreno-Lledo A, Urionaguena I, Dickson AJ. Treat to target in gout. RHEUMATOLOGY. 2018; 57(1): 20 - 26. FI: 5,245(Q1). DOI: 10.1093/rheumatology/kex442. REVIEW.

Latourte A, Soumare A, Bardin T, Perez-Ruiz F, Debette S, Richette P. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann. Rheum. Dis. 2018; 77(3): 328 - 335. FI: 12,350(Q1). DOI: 10.1136/annrheumdis-2016-210767.

Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Validation of a Definition of Flare in Patients With Established Gout. Arthritis Rheumatol. 2018; 70(3): 462 - 467. FI: 7,871(Q1). DOI: 10.1002/art.40381.

Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, Carreno L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived; mesenchymal stem cells in refractory rheumatoid arthritis (Cx611):; results of a multicentre, dose escalation, randomised, single-blind,; placebo-controlled phase Ib/Ila clinical trial. Ann Rheum Dis. 2017;76:196-202. FI:12,811(Q1). DOI:10.1136/annrheumdis-2015-208918.

Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories 1990-2015:a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017;390:231-66. FI:47,831(Q1). DOI:10.1016/S0140-6736(17)30818-8.

Chinchilla S, Urionaguena I and Perez-Ruiz F. Are We Ready? Changes in the Profile of Gout Patients over the Last 25; Years. Arthritis Rheumatol. 2017; . FI: 6,918(Q1). DOI: .

Chinchilla SP, Urionaguena I and Perez-Ruiz F. Ready or not? Changes in the clinical profile of gout patients over the last 25 years. Ann. Rheum. Dis. 2017; 76: 381-0. FI: 12,811(Q1). DOI: 10.1136/annrheumdis-2017-eular.5459.

Cohen S, Alonso-Ruiz A, Klimiuk PA, Lee E, Peter N, Sonderegger I, et al. Similar efficacy and safety of biosimilar candidate bi 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase iii clinical study (Voltaire (R)-RA). Ann Rheum Dis. 2017;76:553. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.3405. ABSTRACT

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis:a randomized double-blind phase III equivalence study. Ann Rheum Dis. 2017;76:1679-87. FI:12,811(Q1). DOI:10.1136/annrheumdis-2016-210459.

Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee E, Peter N, Czeloth N, et al. Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study. Arthritis Rheumatol. 2017;69:2442 . FI:6,918(Q1). ABSTRACT.

Cutolo M, Cimmino MA, Perez-Ruiz F. Potency on lowering serum uric acid in gout patients a pooled analysis of registrative studies comparing febuxostat vs allopurinol. Eur Rev Med Pharmacol Sci. 2017;21:4186-95. FI:1,778(Q3).

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017;69:1903-13. FI:6,918(Q1). DOI:10.1002/art.40159.

Gaffo AL, Dalbeth N, Saag K, Singh JA, Rahn EJ, Mudano AS, et al. Validation of a definition for flare in patients with established gout. Arthritis Rheumatol. 2017;69:2950. FI:6,918(Q1). ABSTRACT

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632-8. FI:12,811(Q1). DOI:10.1136/annrheumdis-2016-209467.

Liu S, Perez-Ruiz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2017;84:183-8. FI:3,329(Q2). DOI:10.1016/j.jbspin.2016.04.007.

Merriman TR, Cadzow M, Merriman ME, Phipps-Green A, Topless R, Abhishek A, et al. A genome-wide association study of gout in people of European ancestry. Arthritis Rheumatol. 2017;69:1104. FI:6,918(Q1). ABSTRACT

Merriman TR, Cadzow M, Merriman M, Phipps-Green A, Topless R, Abhishek A, et al. A genome-wide association study of gout in people of European ancestry. Ann Rheum Dis. 2017;76:383. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.5634. ABSTRACT

Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151-210. FI:47,831(Q1). DOI:10.1016/S0140-6736(17)32152-9.

Nielsen SM, Bartels EM, Henriksen M, Gudbergsen H, Bliddal H, Astrup A, et al. Weight loss for overweight and obese individuals with gout: a systematic; review of longitudinal observational studies. Ann Rheum Dis. 2017;76:1870-82. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-211472.

Nielsen SM, Bartels EM, Henriksen M, Gudbergsen H, Bliddal H, Astrup A, et al. Weight loss for overweight and obese individuals with gout: a systematic; review of longitudinal observational studies. Ann Rheum Dis. 2017;76:196. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.2651. ABSTRACT.

Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Schumacher HR, et al. Performance of ultrasound in the diagnosis of gout in a multicenter study comparison with monosodium urate monohydrate crystal analysis as the gold standard. Arthritis Rheumatol. 2017;69:429-38. FI:6,918(Q1). DOI:10.1002/art.39959.

Perez-Ruiz F. Gota: una oportunidad de intervención en salud. Rev esp econ salud. 2017;12:848-56.

Perez-Ruiz F, Urionagena I and Chinchilla, SP. Long-term adherence to urate-lowering therapy in gout: do not blame on the patients. Ann Rheum Dis. 2017;76:368. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.2994. ABSTRACT.

Perez-Ruiz F. Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort. Rheumatol Ther. 2017;4:419-25. DOI: 0.1007/s40744-017-0082-2.

Perez-Ruiz F, Chinchilla S. Long-term adherence to urate-lowering therapy in gout: do not blame on the patients. Arthritis Rheumatol. 2017;69:1115. FI:6,918(Q1). ABSTRACT

Perez-Ruiz Fe and Chinchilla S. Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout. Arthritis Rheumatol. 2017;69:2068 . FI:6,918(Q1).

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. FI:12,811(Q1). DOI:10.1136/annrheumdis-2016-209707.

Sellas A, Juanola X, Alonso A, Rosas J, Medina J, Collantes E, et al. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatol Int. 2017;37:1817-23. FI:1,824(Q3). DOI:10.1007/s00296-017-3814-2.

Taylor WJ, Dalbeth N, Saag K, Singh JA, Rahn EJ, Mudano AS, et al. Patients with gout consider zero flares over the previous six or twelve; months necessary for a remission state. Arthritis Rheumatol. 2017;69:350. FI:6,918(Q1). ABSTRACT

Urionaguena, I, Chinchilla SP, Erauzkin GG, Muniz-Gomez ML, Perez-Ruiz F. Effect of dialysis and low dose urate-lowering on serum urate levels in; patients with gout. Ann Rheum Dis. 2017;76:1363. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.2980.

Wang HD, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F; GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1084-150. FI:47,831(Q1). DOI:10.1016/S0140-6736(17)31833-0.

Tesis